|
|
Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study |
SHI Jinbo1,2( ),LI Xiawei1,2,WU Yulian1,2,*( ) |
1. Department of Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; 2. Cancer Center, Zhejiang University, Hangzhou 310058, China |
|
|
Abstract Objective:To investigate whether chemotherapy could prolong the postoperative survival time in patients with early stages pancreatic ductal adenocarcinoma (PDAC). Methods:A total of 5280 stage ⅠA -ⅡB PDAC patients diagnosed from 2010 to 2015 were selected from surveillance,epidemiology,and end results (SEER) database. Propensity score matching (PSM) analysis was adopted to reduce the baseline differences between the groups. Univariate survival analysis was conducted with the Kaplan-Meier method. Multivariate survival analysis was performed with the Cox proportional hazards model. Results:Univariate and multivariate survival analyses showed that age, differentiation, stage, chemotherapy were independent risk factors for the survival of PDAC patients. After PSM, it is found that adjuvant chemotherapy could prolong the median overall survival time (mOS) for stage ⅠB, ⅡA and ⅡB patients. However, for stage ⅠA patients, there were no significant differences in 3-year survival rate and mOS between patients with chemotherapy (n=283) and without chemotherapy (n=229) (57.4% vs 55.6%, 44.0?months vs 43.0?months, all P>0.05). Further analyses show that among 101 patients with well differentiated PDAC and 294 patients with moderately differentiated PDAC, there were no significant differences in 3-year survival rate and mOS between patients with and without chemotherapy (allP>0.05). Among 117 patients with low-differentiated + undifferentiated PDAC, 3-year survival rate and mOS in patients with chemotherapy were significantly better than those without chemotherapy (48.5% vs 34.1%, 38.0?months vs 20.0?months, allP<0.05).Conclusion:Chemotherapy regimen used currently is not beneficial for patients with moderately and well differentiated stage ⅠA PDAC, but it is an independent prognostic factor for low-differentiated + undifferentiated PDAC patients.
|
Received: 16 December 2020
Published: 16 August 2021
|
|
Corresponding Authors:
WU Yulian
E-mail: 3130101948@zju.edu.cn;yulianwu@zju.edu.cn
|
基于SEER数据库分析早期胰腺导管腺癌患者能否从常用术后化疗方案中获益
目的:探究术后辅助化疗能否改善早期胰腺导管腺癌(PDAC)患者的生存预后。方法:从监测、流行病学和结果(SEER)数据库中采集2010至2015年诊断为ⅠA~ⅡB期PDAC且接受过手术治疗的5280例患者的资料,通过倾向评分匹配(PSM)减小组间偏倚,用Kaplan-Meier法进行单因素分析及生存分析,采用Cox比例风险模型进行多因素分析。结果:5280例患者的生存分析及多因素分析结果显示,年龄、肿瘤分化、分期、是否化疗是影响PDAC患者预后的独立危险因素。用PSM法减小研究偏倚后共得到ⅠA~ⅡB期病例3738例,进一步行生存分析及多因素分析,提示化疗能够延长ⅠB、ⅡA、ⅡB期患者的术后中位生存时间,而不能改善ⅠA期患者的生存预后。其中ⅠA期共512例,接受化疗者与未化疗者3年存活率和中位生存时间差异均无统计学意义(分别为57.4%和44.0个月与55.6%和43.0个月,均P>0.05);高分化组和中分化组接受化疗者与未化疗者3年存活率和中位生存时间差异均无统计学意义(均P>0.05),而低分化+未分化组接受化疗者3年存活率和术后中位生存时间均高于未化疗者(分别为48.5%和38.0个月与34.1%和20.0个月,均P<0.05)。结论:高、中分化的ⅠA期PDAC患者不能从当前常用的术后化疗方案中获益,但术后化疗是低分化+未分化ⅠA期PDAC患者预后的独立影响因素。
关键词:
胰腺导管腺癌,
SEER数据库,
化学药物治疗,
疾病分期,
肿瘤分化,
预后,
生存分析
|
|
[1] |
SIEGELR L, MILLERK D, JEMALA. Cancer statistics, 2018[J]CA-Cancer J Clin, 2018, 68( 1): 7-30.
doi: 10.3322/caac.21442
|
|
|
[2] |
CHENW, ZHENGR, BAADEP D, et al.Cancer statistics in China, 2015[J]CA-Cancer J Clin, 2016, 66( 2): 115-132.
doi: 10.3322/caac.21338
|
|
|
[3] |
American Cancer Society. Cancer facts & figures 2020[EB/OL]. [2020-11-01]. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html
|
|
|
[4] |
VINCENTA, HERMANJ, SCHULICKR, et al.Pancreatic cancer[J]Lancet, 2011, 378( 9791): 607-620.
doi: 10.1016/S0140-6736(10)62307-0
|
|
|
[5] |
National Comprehensive Cancer Network. Pancreatic adenocarcinoma (Version 3.2019)[EB/OL]. [2020-10-01]. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
|
|
|
[6] |
SAUNGM T, ZHENGL. Current standards of chemotherapy for pancreatic cancer[J]Clin Ther, 2017, 39( 11): 2125-2134.
doi: 10.1016/j.clinthera.2017.08.015
|
|
|
[7] |
SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-648
|
|
|
[8] |
CHAKRABARTIS, PETERSONC Y, SRIRAMD, et al.Early stage colon cancer: current treatment standards, evolving paradigms, and future directions[J]World J Gastrointest Oncol, 2020, 12( 8): 808-832.
doi: 10.4251/wjgo.v12.i8.808
|
|
|
[9] |
SHAIBW L, NARAYANA S, SWITCHENKOJ M, et al.Role of adjuvant therapy in resected stage ⅠA subcentimeter (T1a/T1b) pancreatic cancer[J]Cancer, 2019, 125( 1): 57-67.
doi: 10.1002/cncr.31787
|
|
|
[10] |
ZHANGY, XUG, CHENM, et al.Stage ⅠA patients with pancreatic ductal adenocarcinoma cannot benefit from chemotherapy: a propensity score matching study[J]Front Oncol, 2020, 1018.
doi: 10.3389/fonc.2020.01018
|
|
|
[11] |
BADIYANS N, MOLITORISJ K, CHUONGM D, et al.The role of radiation therapy for pancreatic cancer in the adjuvant and neoadjuvant settings[J]Surg Oncol Clin N Am, 2017, 26( 3): 431-453.
doi: 10.1016/j.soc.2017.01.012
|
|
|
[12] |
BRUNNERT B, SEUFFERLEINT. Pancreatic cancer chemoradiotherapy[J]Best Pract Res Clin Gastroenterol, 2016, 30( 4): 617-628.
doi: 10.1016/j.bpg.2016.08.001
|
|
|
[13] |
OETTLEH, NEUHAUSP, HOCHHAUSA, et al.Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer[J]JAMA, 2013, 310( 14): 1473-1481.
doi: 10.1001/jama.2013.279201
|
|
|
[14] |
NEOPTOLEMOSJ P, PALMERD H, GHANEHP, et al.Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial[J]Lancet, 2017, 389( 10073): 1011-1024.
doi: 10.1016/S0140-6736(16)32409-6
|
|
|
[15] |
NEOPTOLEMOSJ P, STOCKEND D, BASSIC, et al.Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection[J]JAMA, 2010, 304( 10): 1073-1081.
doi: 10.1001/jama.2010.1275
|
|
|
[16] |
CONROYT, HAMMELP, HEBBARM, et al.Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer[J]N Engl J Med, 2018, 379( 25): 2395-2406.
doi: 10.1056/NEJMoa1809775
|
|
|
[17] |
MOTOIF, KOSUGET, UENOH, et al.Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)[J]Jpn J Clin Oncol, 2019, 49( 2): 190-194.
doi: 10.1093/jjco/hyy190
|
|
|
[18] |
NAGAIK, ADACHIT, HARADAH, et al.Dendritic cell-based immunotherapy pulsed with wilms tumor 1 peptide and mucin 1 as an adjuvant therapy for pancreatic ductal adenocarcinoma after curative resection: a phase I/Iia clinical trial[J]Anticancer Res, 2020, 40( 10): 5765-5776.
doi: 10.21873/anticanres.14593
|
|
|
[19] |
BOCKORNYB, SEMENISTYV, MACARULLAT, et al.BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial[J]Nat Med, 2020, 26( 6): 878-885.
doi: 10.1038/s41591-020-0880-x
|
|
|
[20] |
VENNINC, MéLéNECP, ROUETR, et al.CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan[J]Nat Commun, 2019, 10( 1): 3637.
doi: 10.1038/s41467-019-10968-6
|
|
|
[21] |
MATSUMOTOG, MUTAM, KOJITSURUTAM, et al.Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer[J]Pancreatology, 2007, 7( 2-3): 167-173.
doi: 10.1159/000104241
|
|
|
[22] |
田景媛, 李孔玲, 陈罗军, 等. 胰腺导管腺癌术后患者Nomogram预后模型的构建[J]. 现代肿瘤医学, 2019, 27(9): 114-118 TIAN Jingyuan, LI Kongling, CHEN luojun, et al. The establishment of a prognostic Nomogram for resected pancreatic ductal adenocarcinoma[J]. Journal of Modern Oncology, 2019, 27(9):114-118. (in Chinese)
|
|
|
[23] |
ASAOKAT, MIYAMOTOA, MAEDAS, et al.Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer[J]Pancreatology, 2016, 16( 3): 434-440.
doi: 10.1016/j.pan.2015.10.006
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|